{"id":"W4285027377","doi":"10.1080/10428194.2022.2095624","title":"PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design","year":2022,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Janssen Biotech; Chugai Pharmaceutical; H. Lundbeck A/S; Servier; Incyte; AbbVie; Takeda Pharmaceutical Company; Teva Pharmaceutical Industries; Sandoz; MorphoSys; Celgene; Seattle Genetics; Karyopharm Therapeutics; Gilead Sciences; Merck; TG Therapeutics; Amgen","keywords":"Chemoimmunotherapy; Hazard ratio; Medicine; Internal medicine; Clinical trial; Diffuse large B-cell lymphoma; Clinical endpoint; Oncology; Meta-analysis; Progression-free survival; Sample size determination; Surrogate endpoint; Proportional hazards model; Overall survival; Confidence interval; Lymphoma; Nuclear medicine; Rituximab; Statistics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04451019,0.001842511,0.01175647,0.002336554,0.0002306846,0.003008172,0.001759725,0.00210958,0.002330795],"category_scores_gemma":[0.07351994,0.0008945313,0.02057596,0.002764404,0.0004625996,0.001622507,0.0008943531,0.002574994,0.0002426804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001657098,"about_ca_system_score_gemma":0.002238347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002041626,"about_ca_topic_score_gemma":0.00364255,"domain_scores_codex":[0.9725468,0.02335103,0.002278735,0.0007974053,0.0008370339,0.0001889851],"domain_scores_gemma":[0.9407324,0.05450604,0.002335051,0.00117532,0.001013926,0.0002372695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.005412405,0.00005274999,0.003758636,0.2216784,0.6626626,0.0001114575,0.00007116359,0.003850864,0.0002829552,0.001659692,0.002204075,0.09825498],"study_design_scores_gemma":[0.003207264,0.0006194726,0.003834976,0.03025498,0.9427082,0.0001630502,0.00005249137,0.002945204,0.0003190524,0.006744083,0.009099513,0.00005155706],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001365023,0.9952402,0.002073207,0.000564284,0.0001820987,0.0001534005,0.0001187192,0.00002324456,0.000279841],"genre_scores_gemma":[0.1611075,0.8249764,0.008437978,0.002375877,0.0006266552,0.001399677,0.0005751828,0.00006594336,0.0004348106],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.04451019,"threshold_uncertainty_score":0.2353953,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.206374533336237,"score_gpt":0.4167294272308164,"score_spread":0.2103548938945794,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}